Deepak joined Foresite in 2022 as a member of the investment team. His work focuses on company formation based on new scientific and clinical directions, as well as public and private therapeutics company investment. Most notably, Deepak led the in-licensing of the BCMA T cell engager (TCE) into Vignette Bio, a Foresite Labs incubated-company, which was subsequently merged with Candid Therapeutics (acquired by UCB).
He is a board observer for Slate Medicines and Mammoth Biosciences. He previously served as a board observer for Candid Therapeutics.
Prior to joining Foresite, Deepak trained as a physician-scientist. He completed his MD at Yale, where he was a Howard Hughes Medical Institute research fellow. He then completed internal medicine residency at The Johns Hopkins Hospital, cardiovascular medicine fellowship at the Brigham and Women’s Hospital / Harvard Medical School, as well as a postdoctoral fellowship in molecular and population genetics at the Broad Institute of MIT & Harvard. His work has appeared in journals such as Nature, Nature Genetics, and The New England Journal of Medicine. Deepak continues to see patients in cardiovascular medicine and cardiovascular genetics clinics.